CELEX: 62017TA0103
Language: en
Date: 2018-03-09 00:00:00
Title: Case T-103/17: Judgment of the General Court of 9 March 2018 — Recordati Orphan Drugs v EUIPO — Laboratorios Normon (NORMOSANG) (EU trade mark — Opposition proceedings — Application for EU word mark NORMOSANG — Earlier national word mark NORMON — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) — Rule 19(2)(a)(ii) and Rule 20(1) of Regulation (EC) No 2868/95 (now Article 7(2)(a)(ii) and Article 8(1) and (7) of Delegated Regulation (EU) 2017/1430))

23.4.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 142/49
            
         Judgment of the General Court of 9 March 2018 — Recordati Orphan Drugs v EUIPO — Laboratorios Normon (NORMOSANG)
   (Case T-103/17) (1)
   
   ((EU trade mark - Opposition proceedings - Application for EU word mark NORMOSANG - Earlier national word mark NORMON - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) - Rule 19(2)(a)(ii) and Rule 20(1) of Regulation (EC) No 2868/95 (now Article 7(2)(a)(ii) and Article 8(1) and (7) of Delegated Regulation (EU) 2017/1430)))
   (2018/C 142/65)
   Language of the case: English
   
      Parties
   
   
      Applicant: Recordati Orphan Drugs (Puteaux, France) (represented by: J. Quirin, lawyer)
   
      Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė, acting as Agent)
   
      Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Laboratorios Normon, SA (Tres Cantos, Spain) (represented by: I. Gonzalez-Mogena Gonzalez, lawyer)
   
      Re:
   
   Action brought against the decision of the Fifth Board of Appeal of EUIPO of 22 November 2016 (Case R 831/2016-5), relating to opposition proceedings between Laboratorios Normon and Recordati Orphan Drugs.
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Dismisses the action;
            
         
               2.
            
            
               Orders Recordati Orphan Drugs to pay the costs.
            
         
      (1)  OJ C 121, 18.4.2017.